Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.
COVID-19
SARS-CoV-2
coronavirus
humoral immune response
neutralizing antibody
protective immunity
receptor-binding protein
serology test
spike protein
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
23 06 2020
23 06 2020
Historique:
received:
29
04
2020
revised:
28
05
2020
accepted:
29
05
2020
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
25
8
2020
Statut:
ppublish
Résumé
SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there is a pressing need to understand the development, specificity, and neutralizing potency of humoral immune responses during acute infection. We report a cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients. RBD-specific IgG responses are detectable in all patients 6 days after PCR confirmation. Isotype switching to IgG occurs rapidly, primarily to IgG1 and IgG3. Using a clinical SARS-CoV-2 isolate, neutralizing antibody titers are detectable in all patients by 6 days after PCR confirmation and correlate with RBD-specific binding IgG titers. The RBD-specific binding data were further validated in a clinical setting with 231 PCR-confirmed COVID-19 patient samples. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.
Identifiants
pubmed: 32835303
doi: 10.1016/j.xcrm.2020.100040
pii: S2666-3791(20)30052-5
pii: 100040
pmc: PMC7276302
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100040Subventions
Organisme : NIAID NIH HHS
ID : R38 AI140299
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008169
Pays : United States
Organisme : NIA NIH HHS
ID : R00 AG049092
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI057266
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI074492
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Organisme : NIAID NIH HHS
ID : R24 AI120942
Pays : United States
Organisme : NIAID NIH HHS
ID : K99 AI153736
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137127
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI090023
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI148576
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
Nature. 2013 Aug 8;500(7461):227-31
pubmed: 23831647
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9
pubmed: 15210961
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Curr Opin Virol. 2011 Dec;1(6):624-34
pubmed: 22180768
JAMA. 2020 Mar 27;:
pubmed: 32219428
Adv Virus Res. 2019;105:93-116
pubmed: 31522710
Science. 2005 Sep 16;309(5742):1864-8
pubmed: 16166518
J Virol. 2008 Apr;82(7):3220-35
pubmed: 18199635
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
J Virol. 2003 Aug;77(16):8801-11
pubmed: 12885899
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Infect Dis. 2006 Mar 15;193(6):792-5
pubmed: 16479513
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
PLoS Med. 2006 Dec;3(12):e525
pubmed: 17194199
Nat Protoc. 2009;4(3):372-84
pubmed: 19247287
J Infect. 2020 Aug;81(2):e55-e58
pubmed: 32335168
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480